ReviewBioMed research international2014
Application of microRNA in diagnosis and treatment of ovarian cancer.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Identification of core genes in ovarian cancer by an integrative meta-analysis.Journal of ovarian research · 2018Pooled it
- Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis.Oncotarget · 2017Pooled it
- Metabolic activation of LDHA by ERRα represses inflammasome-dependent pyroptosis and promotes ovarian cancer chemoresistance.Cell death & disease · 2026Article
- A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy.JCI insight · 2022Article
- Wnt antagonist as therapeutic targets in ovarian cancer.The international journal of biochemistry & cell biology · 2022Review
- New Approaches and Biomarker Candidates for the Early Detection of Ovarian Cancer.Frontiers in bioengineering and biotechnology · 2022Article
- Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics.Therapeutic advances in medical oncology · 2022Review
- Myricetin Suppresses Ovarian CancerFrontiers in oncology · 2022Article
- Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer.BMC pharmacology & toxicology · 2021Article
- MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.International journal of molecular sciences · 2021Review
- Overexpression of Galectin10 Predicts a Better Prognosis in Human Ovarian Cancer.Journal of Cancer · 2021Article
- Modulatory Role of Vaginal-Isolated Lactococcus lactis on the Expression of miR-21, miR-200b, and TLR-4 in CAOV-4 Cells and In Silico Revalidation.Probiotics and antimicrobial proteins · 2020Article
- Review
- MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.Journal of experimental & clinical cancer research : CR · 2020Article
- The overexpression of lncRNA MEG3 inhibits cell viability and invasion and promotes apoptosis in ovarian cancer by sponging miR-205-5p.International journal of clinical and experimental pathology · 2020Article
- miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.Oncogene · 2019Article
- MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27.Cellular & molecular biology letters · 2019Article
- Biological Function of Ribosomal Protein L10 on Cell Behavior in Human Epithelial Ovarian Cancer.Journal of Cancer · 2018Article
- Upregulation of microRNA-4417 and Its Target Genes Contribute to Nickel Chloride-promoted Lung Epithelial Cell Fibrogenesis and Tumorigenesis.Scientific reports · 2017Article
- miR-214 promotes radioresistance in human ovarian cancer cells by targeting PETN.Bioscience reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.